Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 403 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Part 1 Clear all
Not listed Phase 1Phase 2 Interventional

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

NCT01154387
View directory record Official record
Conditions
End Stage Renal Disease, Renal Transplant
Interventions
Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Tolera Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 2 Interventional Results available

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

NCT00219557
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Gemcitabine, AG-013736
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
17
States / cities
Antioch, California • Berkeley, California • Concord, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 2 Interventional Results available

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

NCT04345614
View directory record Official record
Conditions
Pneumonia
Interventions
Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2), Placebo (Part 2)
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 11:20 PM EDT
Terminated Phase 1Phase 2 Interventional

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

NCT04409145
View directory record Official record
Conditions
Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions
VT30
Drug
Lead sponsor
Venthera, Inc., a BridgeBio company
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Results available

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167
View directory record Official record
Conditions
Viral Disease
Interventions
PF-07304814, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Mountain View, California • Newport Beach, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 22, 2026, 11:20 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

NCT05521022
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
AT-02, AT-02 (Placebo)
Drug · Other
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Overland Park, Kansas • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine

NCT05486949
View directory record Official record
Conditions
Healthy Subjects
Interventions
AZD4205 and carbamazepine, AZD4205 and itraconazole
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

NCT03279302
View directory record Official record
Conditions
Healthy Subjects
Interventions
Glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Combined School- and Home-Based Sleep Promotion Program

NCT06131944
View directory record Official record
Conditions
Sleep
Interventions
Rested & Ready to Learn
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
4 Years to 6 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])

NCT02384200
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infections
Interventions
nitrofurantoin monohydrate/macrocrystalline capsules, ampicillin, gentamicin, vancomycin, ceftriaxone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 22, 2026, 11:20 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 2 Interventional

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

NCT05717920
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ADX-629 (Open-label)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 22, 2026, 11:20 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

NCT07680686
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 11:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT06610279
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

NCT01290679
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 2 Interventional

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

NCT01728220
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

NCT04008004
View directory record Official record
Conditions
Chronic HBV Infection
Interventions
EDP-514, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
11
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

NCT01413932
View directory record Official record
Conditions
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions
HT-2157, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

NCT05628740
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]
Drug
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

NCT01712828
View directory record Official record
Conditions
Healthy
Interventions
Lenalidomide, Quinidine, Temsirolimus, Diphenhydramine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 22, 2026, 11:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions
BNT323, BNT327
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

NCT03355209
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 22, 2026, 11:20 PM EDT